Actively Recruiting
IVIG vs SCIG in CIDP
Led by Rutgers, The State University of New Jersey · Updated on 2025-12-11
20
Participants Needed
1
Research Sites
220 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
CONDITIONS
Official Title
IVIG vs SCIG in CIDP
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged >18 years with a current diagnosis of CIDP based on European Federation of Neurological sciences / Peripheral Nerve Society diagnostic criteria
- 1:1 conversion of IVIG to SCIG with weekly dose conversion within 0.2 to 0.4 mg/kg dose for SCIG
You will not qualify if you...
- Patients receiving IVIG for indications other than CIDP
- Patients with liver impairment with liver enzymes greater than 3 times the upper limit of normal
- Patients with reduced kidney function with creatinine clearance less than 50 mL/min
- Active malignancies
- Diabetes
- Myasthenia gravis
- Immunodeficiency
- Autoimmune disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rutgers, The State University of New Jersey Clinical Research Center
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
Research Team
L
Luigi Brunetti, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here